畜禽支原体耐药性及耐药机制研究进展

doi:10.16431/j.cnki.1671-7236.2017.08.038

摘要/Abstract

摘要：

支原体感染给畜禽养殖造成的危害已受到国内外科研人员的广泛重视。目前控制畜禽支原体感染、降低畜禽养殖经济损失的切实有效方法是大量使用抗生素，其中四环素、大环内酯类及喹诺酮类药物是现阶段临床兽医首选的3类抗菌药。但短短几十年的临床实践表明，滥用抗生素已经严重威胁畜禽健康，许多畜禽支原体临床分离株不仅仅对单一抗生素产生耐药性，而且同时对多种抗生素耐药。作者从药物靶位点改变、外排泵系统形成、抗菌药物灭活酶产生等方面对上述抗畜禽支原体药物的耐药机制进行阐述，以期为建立支原体耐药性检测体系、指导临床合理用药、开发新的药物等提供理论依据和策略。

关键词: 畜禽; 支原体; 耐药性; 耐药机制

Abstract:

The harm for livestock and poultry production caused by Mycoplasma infection has got widespread attention of researchers in the world. The practical ways to control the disease in order to reduce economic loss through Mycoplasma infection is the extensive use of antibiotics. Many groups of antibiotics including tetracyclines, macrolides and quinolones have been shown to be effective to Mycoplasma. Clinical practice shows many Mycoplasma isolated from livestock and poultry are characterized not only by single drug resistance but also by multiple antibiotic resistance due to the legacy of past decades of antimicrobial misuse, which threat the livestock and poultry production health. This paper reviews the mechanism of anti-Mycoplasma medicines through the alterations in the targets, the formation of efflux pump system, and the generation of inactivated enzymes of antibiotics, which provide theoretical basis and strategies for establishing resistance testing system, rational drug use and development of new drugs.

Key words: livestock and poultry; Mycoplasma; drug resistance; drug-resistant mechanism

中图分类号:

S852.62

宫晓炜, 马文瑛, 陈启伟, 郑福英, 刘永生. 畜禽支原体耐药性及耐药机制研究进展[J]. 《中国畜牧兽医》, 2017, 44(8): 2489-2495.

GONG Xiao-wei, MA Wen-ying, CHEN Qi-wei, ZHENG Fu-ying, LIU Yong-sheng. Research Progress on Drug Resistance and Its Mechanism of Mycoplasma in Livestock and Poultry[J]. , 2017, 44(8): 2489-2495.

参考文献

[1] Blanchard A, Browning G. Mycoplasma:Molecular Biology, Pathogenicity and Strategies for Control[M]. Boca Raton:CRC Press, 2005.
[2] 吴移谋,叶元康. 支原体学[M]. 北京:人民卫生出版社,2008.
[3] Whithear K G. Control of avian Mycoplasmoses by vaccination[J]. Rev Sci Tech, 1996, 15(4):1527-1253.
[4] Kong L C, Gao D, Jia B Y, et al. Antimicrobial susceptibility and molecular characterization of macrolide resistance of Mycoplasma bovis isolates from multiple provinces in China[J]. J Vet Med Sci, 2016, 78(2):293-296.
[5] Dusˇanic' D, Ber?i? RL, Cizelj I, et al. Mycoplasma synoviae invades non-phagocytic chicken cells in vitro[J]. Vet Microbiol, 2009, 138(1-2):114-119.
[6] 翟文海,刘汉丹,张燕. 支原体对大环内酯类药物体外耐药性调查[J]. 实用临床医药杂志,2006,10(4):17-18.
[7] 陈杖榴,吴聪明,蒋红霞,等. 兽用抗菌药物耐药性研究[J]. 四川生理科学杂志,2003,25(3):120-123.
[8] Al-Momani W, Nicgolas R A, Janakat S, et al. The in vitro effect of six antimicrobials against Mycoplasma putrefaciens, Mycoplasma mycoides subsp.mycoides LC and Mycoplasma capricolum subsp. capricolum isolated from sheep and goats in Jordan[J]. Trop Anim Health Prod, 2006, 38(1):1-7.
[9] 程光胜,王豪举. 山羊传染性胸膜肺炎病原的分离鉴定与药敏试验[J].中国畜牧兽医,2006,33(9):68-70.
[10] 宋勤叶,张英杰,刘月琴,等. 18种抗菌药物对绵羊肺炎支原体和丝状支原体分离株的抗菌活性[J]. 动物医学进展,2011,32(6):14-18.
[11] Antunes N T, Assunção P, Poveda J B, et al. Mechanisms involved in quinolone resistance in Mycoplasma mycoides subsp.capri[J]. Vet J, 2015, 204(3):327-332.
[12] Pereyre S, Guyot C, Renaudin H, et al. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumonia[J]. Antimicrob Agents Chemother, 2004, 48(2):460-465.
[13] Shang R F, Xu S J, et al. Syntheses crystal structures and antibacterial evaluation of two new pleuromutilin derivatives[J]. Chinese Journal of Structural Chemistry, 2016, 35:529-536.
[14] Roman P, Branimir N, Krasimira G E, et al. The coparative therapeutic efficacy of antimicrobials in pigs infected with Mycoplasma Hyopneumoniae[J]. Pathol, 2016, 41:624-640.
[15] Ayling R D, Rosales R S, Barden G, et al. Changes in antimicrobial susceptibility of Mycoplasma bovis isolates from Great Britain[J]. Vet Rec, 2014, 175(19):86.
[16] Gautier-Bouchardon A V, Ferré S, Le Grand D, et al. Overall decrease in the susceptibility of Mycoplasma bovis to antimicrobials over the past 30 years in France[J]. PLoS One, 2014,9(2):e87672.
[17] Ricardo F R, Joann M K, Michael A. In vitro antimicrobial inhibition profiles of Mycoplasma bovis isolates recovered from various regions of the United States from 2002 to 2003[J]. J Vet Diagn Invest, 2005, 17(5):436-441.
[18] Soehnlen M, Kunze M, Karunathilak K, et al. In vitro antimi crobial inhibition of Mycoplasma bovis isolates submitfed to the Pennsylvania Animal Diagnostic Laboratory using flow cytometry and abroth microdilution method[J]. J Vet Diagn Invest, 2011, 23:547-551.
[19] Sulyok M K, Kreizinger Z, Fekete L, et al. Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in hungary, central Europe[J]. BMC Vet Res, 2014, 10:256.
[20] 孔令聪,张春艳,高云航,等. 牛支原体耐药性研究进展[J]. 中国兽药杂志,2013,47(9):63-65.
[21] 贺晨飞,Mustafa R,陈颖钰,等. 牛支原体体外药物敏感性分析[J]. 中国奶牛,2015,16:32-35.
[22] Gerchman I, Lysnyansky I, Perk S. In vitro susceptibilities to fluoroquinolones in current and archived Mycoplasma gallisepticum and Mycoplasma synoviae isolates from meat-type turkey[J]. Vet Microbiol, 2008, 131(3-4):266-276.
[23] Landman W J M, Mevius J, Veldman K T. In vitro antibiotic susceptibility of Dutch Mycoplasma synoviae field isolates originating from joint lesions and the respiratory tract of commercial poultry[J]. Avian Pathol, 2008, 37(4):415-420.
[24] Lysnyansky I, Gerchman I, Mikula I, et al. Molecular characterization of acquired enrofloxacin resistance in Mycoplasma synoviae field isolates[J]. Antimicrob Agents Chemother, 2013, 57(7):3072-3077.
[25] 丁美娟,卢凤英,严鹏,等. 鸡滑液囊支原体不同地区分离株对常用抗菌药物的敏感性试验[J]. 中国兽药杂志,2015,49(10):52-55.
[26] 向蓉,丁焕中,曾振灵. 鸡源大肠杆菌、支原体对几种抗菌药物的耐药性调查[J]. 养禽与禽病防治,2006,11:21-22.
[27] Ikonomidis A, Venetis C, Georgantzis D, et al. Prevalence of Chlamydia trachomatis, Ureaplasma spp., Mycoplasma genitalium and Mycoplasma hominis among outpatients in central Greece:Absence of tetracycline resistance gene tet(M) over a 4 year period study[J]. New Microbe and New Infect, 2016, 9:8-10.
[28] Beeton M L, Chalker V J, Maxwell N C, et al. Concurrent titration and determination of antibiotic resistance in Ureaplasma species with identification of novel point mutations in genes associated with resistance[J]. Antimicrob Agents Chemother, 2009, 53(5):2020-2027.
[29] Amram E, Mikula I, Schnee C,et al. 16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis[J]. Antimicrob Agents Chemother, 2015, 59(2):796-802.
[30] Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA[J]. Antimicrob Agents Chemother, 2001, 45(1):1-12.
[31] Li B B, Shen J Z, Cao X Y, et al. Mutations in 23S rRNA gene associated with decreased susceptibility to tiamulin and valnemulin in Mycoplasma gallisepticum[J]. Fems Microbiol Lett, 2010, 308(2):144-149.
[32] 吴惠明,吴聪明,沈建忠,等. 鸡毒支原体红霉素和替米考星耐药体外诱导及其23S rRNA基因Ⅴ域突变特征分析[J]. 中国兽医杂志,2006,42(7):12-14.
[33] 刘轶秋,吴聪明,沈建忠,等. 3种禽源支原体替米考星耐药株的体外诱导及23S rRNA基因Ⅴ域碱基突变分析[J]. 畜牧兽医学报,2011,42(7):981-987.
[34] Lysnyansky I, Gerchman I, Flaminio B, et al. Decreased susceptibility to macrolide-lincosamide in Mycoplasma synoviae is associated with mutations in 23S ribosomal RNA[J]. Microb Drug Resist, 2015, 21(6):581-589.
[35] Kobayashi H, Nakajima H, Shimizu Y, et al. Macrolides and lincomycin susceptibility of Mycoplasma hyorhinis and variable mutation of domain Ⅱ and Ⅴ in 23S ribosomal RNA[J]. J Vet Med Sci, 2005, 67(8):795-800.
[36] Stakenborgt T, Vicca J, Bbtaye P, et al. Characterization of in vivo acquired resistance of Mycoplasma hyopneumoniae to macrolides and lincosamides[J]. Microb Drug Resist, 2005, 11:290-294.
[37] 吴惠明. 耐大环内酯类药物鸡毒支原体的诱导和耐药基因的突变分析[D]. 北京:中国农业大学,2004.
[38] 王建国. 鸡毒支原体大环内酯类耐药性诱导及其核蛋白突变分析[D]. 北京:中国农业大学,2006.
[39] Lerner U, Amrama E, Ayling R D, et al. Acquired resistance to the 16-membered macrolides tylosin and tilmicosin by Mycoplasma bovis[J]. Vet Microbiol, 2014, 168(2-4):365-371.
[40] 高铎. 牛支原体的分离鉴定及对大环内酯类抗生素耐药机制研究[D]. 长春:吉林农业大学,2015.
[41] Hideaki I, Hiroaki Y, Mayumi B S, et al. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus[J]. Antimicrob Agents and Chemother, 1994, 38(9):2014-2023.
[42] Reinhardt A K, Bebear C M, Kobis ch M, et al. Characterization of mutations in DNA gyrase and topoisomerase Ⅳ involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro[J]. Antimicrob Agents and Chemother, 2002, 46(2):590-593.
[43] 蒋红霞,陈杖榴,曾振灵,等. 氟喹诺酮类药物压力下鸡毒支原体gyrA基因突变特征分析[J]. 中国兽医杂志,2004,40(10):60-62.
[44] 林居纯,曾振灵,蒋红霞. 耐氟喹诺酮类药物鸡毒支原体gyrA基因突变的研究[J]. 中国兽医杂志,2007, 43(5):18-20.
[45] 魏飞龙,周云雷,沈祥广,等. 耐氟喹诺酮类药物鸡毒支原体DNA回旋酶及拓扑异构酶Ⅳ的突变特征[J]. 中国畜牧兽医,2010,37(8):43-47.
[46] Sato T, Okubo T, Usui M, et al. Amino acid substitutions in GyrA and ParC are associated with fluoroquinolone resistance in Mycoplasma bovis isolates from Japanese dairy calves[J]. J Vet Med Sci, 2013, 75(8):1063-1065.
[47] Vicca J, Maes D, Stakenborg T, et al. Resistance mechanism against fluoroquinolones in Mycoplasma hyopneumoniae field isolates[J]. Microb Drug Resist, 2007, 13(3):166-170.
[48] 朱阵,曹明泽,张吉丽,等. 细菌耐药性研究进展[J].中国畜牧兽医, 2015,42(12):3371-3376.
[49] 周云,凌保东. 4种外排泵抑制剂对鲍曼不动杆菌耐药性的抑制影响[J]. 中国抗生素杂志,2013,38(6):461-466.